ADMA's profit rose 37%. Where is the cash going?
ASCENIV lifted margins and the earnings outlook. Quarterly cash flow improved too, but inventory and customer balances kept it far below profit.
ADMA Biologics earned $49.9 million in the third quarter, up 37% from a year earlier, as higher ASCENIV sales lifted the group's profit margin. The cash arriving from operations was much smaller: $17.4 million.
Research by Ticker Byline shows that most of ADMA's year-to-date cash-flow rebound had already happened before the third quarter. Comparing its November and August financial statements isolates a quarter in which inventory and unpaid customer balances absorbed $57.8 million. That helps explain why higher earnings have yet to produce a similar amount of spendable cash.
The ADMA company profile tracks the drugmaker's product mix, cash needs and earlier forecasts. Its plasma-derived medicines treat people with immune deficiencies, and production can take seven to 12 months or longer from raw materials to a saleable product.
More profit from a different sales mix
ASCENIV revenue rose 31% to $124.7 million in the quarter ended September 30. That pushed gross margin, the share of revenue left after product costs, to 70.8% from 56.3% a year earlier. Management attributes the improvement to a greater share of higher-margin ASCENIV sales and a manufacturing process that produces more medicine from the same plasma volume.
Total revenue grew just 5% to $141.1 million because the other products weakened. BIVIGAM sales fell 35% to $15.4 million, while intermediates and other products fell to $0.9 million from $15.0 million.
BIVIGAM also slipped from $19.4 million in Q2, after management had described stabilization in August. President and Chief Executive Officer Adam S. Grossman now points to encouraging stabilization in end-user use entering Q4, while competitive pricing and distributor inventories continue to weigh on sales.
The quarterly cash picture
ADMA generated $105.2 million in operating cash over nine months, compared with $14.8 million a year earlier. About 95% of that year-on-year improvement came in the first half. Third-quarter cash flow still increased 31%, but represented about 35% of the quarter's profit.
| Measure | 2026 | 2025 |
|---|---|---|
| Net income, GAAP | 49.9 | 36.4 |
| Operating cash flow, GAAP | 17.4 | 13.3 |
| Inventory cash use | 26.8 | 5.2 |
| Receivables cash use | 31.0 | 27.9 |
Customer collections had released $20.2 million in the first half. In Q3, receivables instead absorbed $31.0 million. Inventory consumed another $26.8 million, taking the September balance to $266.1 million. The production cycle explains part of the need to hold stock, but finished goods also increased to $87.8 million from $52.1 million at year-end.
Buybacks draw on more than operating cash
ADMA spent $180.3 million in cash on share repurchases through September, exceeding its nine-month operating cash flow. A $125 million revolving-credit borrowing in March funded its accelerated repurchase, which settled in May. The company still targets at least $200 million of repurchases for 2026.
September cash was $124.6 million, with $197.2 million of debt principal and $100 million undrawn on its committed revolving facility. Its credit facilities mature in August 2028, and ADMA reported compliance with the loan conditions.
The improved product mix led ADMA to lift its 2026 minimum adjusted net-income expectation to $180 million from August's $170 million lower bound. The revenue minimum remains $530 million. August used ranges of $170 million to $200 million for adjusted profit and $530 million to $560 million for revenue; November states minimums.
Adjusted net income removes specified items such as certain professional fees and yield-enhancement costs, while retaining ordinary stock compensation. For the next results, the useful test is whether the group's higher profit margin is accompanied by customer collections and inventory moving through to sales.